MaxCyte, Inc. Notice of AGM and 2016 Annual Report and Accounts (4800C)
13 April 2017 - 10:00PM
UK Regulatory
TIDMMXCT
RNS Number : 4800C
MaxCyte, Inc.
13 April 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of AGM and 2016 Annual Report and Accounts
Maryland, USA - 13 April 2017: MaxCyte (LSE: MXCT), a US-based
global company dedicated to driving the acceleration of the
discovery, development, manufacturing and commercialization of
next-generation, cell-based medicines, gives notice that copies of
the 2016 Annual Report and Accounts and the Notice of Annual
General Meeting have been sent to shareholders. These documents are
available on the "Investors" section of the Company's website at
www.maxcyte.com.
Further copies of the Annual Report will be available from the
Company Secretary, MaxCyte, Inc., 22 Firstfield Road, Suite 110,
Gaithersburg, MD 20878, USA.
MaxCyte also announces that its Annual General Meeting of
Stockholders is planned to be held on 31 October 2017. Formal
notice and resolutions, along with the Annual Meeting Proxy Card,
will be circulated on or about 10 September 2017 to Stockholders of
record on or about that date.
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte (LSE: MXCT) is a US-based global company dedicated to
driving the acceleration of the discovery, development,
manufacturing and commercialisation of next-generation, cell-based
medicines. The Company provides its patented, high-performance cell
engineering platform to biopharmaceutical partners engaged in drug
discovery and development, biomanufacturing, and cell therapy,
including gene editing and immuno-oncology. With its robust
delivery platform, MaxCyte's team of scientific experts helps its
partners to unlock their product potential and solve problems. This
platform allows for the engineering of nearly all cell types,
including human primary cells, with any molecule, at any scale. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large-scale, clinical and
commercial grade cell engineering in a non-viral system and with
low-toxicity concerns. The Company's cell-engineering platform is
FDA-accredited, providing MaxCyte's customers and partners with an
established regulatory path to commercialise cell-based
medicines.
MaxCyte is also developing CARMA, its proprietary, breakthrough
platform in immuno-oncology, to rapidly manufacture CAR therapies
for a broad range of cancer indications, including solid tumors
where existing CAR-T approaches face significant challenges.
For more information, visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSOKNDBDBKDFQD
(END) Dow Jones Newswires
April 13, 2017 08:00 ET (12:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024